19/04/2015 06:59:26 Free Membership Login

Merck News (NYSE:MRK)

04/18/20153:02PMTMF3 Drug Stocks Leading the Charge Against Infectious Diseases
http://www.fool.com/investing/general/2015/04/18/3-drug-stocks-leading-the-charge-against-infectiou.aspx?source=eptadnlnk0000002 More...>>
04/18/201510:02AMTMFWhat Could Possibly Go Wrong With Gilead Sciences Inc. Stock?
http://www.fool.com/investing/general/2015/04/18/what-could-possibly-go-wrong-with-gilead-sciences.aspx?source=eptadnlnk0000002 More...>>
04/16/20158:03AMTMFThe Best Stock to Invest in Hep C
http://www.fool.com/investing/general/2015/04/16/the-best-stock-to-invest-in-hep-c.aspx?source=eptadnlnk0000002 More...>>
04/14/20151:30PMBWPhase III Trial of the Merck and NewLink Genetics Investigational Ebola Vaccine Initiated in Sierra Leone
rVSV-ZEBOV-GP (V920) Now Being Studied in Three Key Safety and Efficacy Clinical Trials Merck (NYSE:MRK), known as MSD outside the United States and Canada, and NewLink Genetics Corporation (NASDAQ: NLNK), confirmed today that the third, late-stage, clinical trial of their Ebola vaccine candidate rVSV-ZEBOV-GP (V920) has... More...>>
04/14/20159:20AMSEEKHeat Biologics Is An Opportunity Among Soaring Immunotherapy Biotech Valuations
http://seekingalpha.com/article/3068836-heat-biologics-is-an-opportunity-among-soaring-immunotherapy-biotech-valuations?source=partner_advfn More...>>
04/14/20158:44AMSEEKThe Growing Business Of Animal Healthcare
http://seekingalpha.com/article/3068696-the-growing-business-of-animal-healthcare?source=partner_advfn More...>>
04/14/20157:00AMGLOBENewLink Genetics and Merck & Co Receives Vaccine Industry Excellence Awards at World Vaccine Congress 2015
- Best Vaccine License - NewLink Genetics and Merck & Co. Ebola Vaccine Licensing Agreement - Best Prophylactic Vaccine - NewLink Genetics and Merck & Co. – rVSV-EBOV for Ebola AMES, Iowa, April 14, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK), a biopharmaceutical company focused on... More...>>
04/13/20159:12PMSEEKThe New Dogs Of The Dow - Q1 2015
http://seekingalpha.com/article/3067476-the-new-dogs-of-the-dow-q1-2015?source=partner_advfn More...>>
04/13/20156:02PMDJNMerck CEO's 2014 Total Compensation Valued at $25 Million -- Update
By Maria Armental And Angela Chen Merck & Co.'s total compensation for its chief executive rose sharply in 2014 to $25 million from the year-ago period, according to a regulatory filing. The pharmaceutical company said Chief Executive Kenneth C. Frazier, who also chairs its board, saw an 87% increase in the value of... More...>>
04/13/20151:40PMDJNFitch Downgrades Merck
Fitch Ratings has downgraded pharmaceutical company Merck & Co's rating to A from A+, though it also revised the outlook to stable from negative, citing improving margins. Shares of Merck were recently down less than 1% in midday trading. The ratings firm expects Merck's leverage--a combination of total debt and Ebitda--to... More...>>
04/12/20153:56PMDJNHow the Hottest Biotech Sprouted in Iowa
By Peter Loftus AMES, Iowa--This state leads the nation in hogs and corn, not biotechnology drugs. But one small firm here is drawing notice for its cutting-edge research on Ebola and cancer, despite being far removed from the drug industry's usual hubs. NewLink Genetics Corp. has recruited scientists from around the world... More...>>
04/12/20159:52AMTMF3 Best Dividend Stocks in Healthcare
http://www.fool.com/investing/general/2015/04/12/3-best-dividend-stocks-in-healthcare.aspx?source=eptadnlnk0000002 More...>>
04/11/20153:51AMSEEKImmunotherapy: Unleashing The Immune System To Decimate Cancer
http://seekingalpha.com/article/3063216-immunotherapy-unleashing-the-immune-system-to-decimate-cancer?source=partner_advfn More...>>
04/09/20155:59PMSEEKWhy Investors Shouldn't Worry About Explosive New Drug Pricing: Maxim's Jason Kolbert
http://seekingalpha.com/article/3060866-why-investors-shouldnt-worry-about-explosive-new-drug-pricing-maxims-jason-kolbert?source=partner_advfn More...>>
04/09/20152:30PMDJNSquabbles Over Testing Methods Hamper Search for Ebola Vaccine
By Thomas M. Burton The Ebola virus outbreak in West Africa created a rare opportunity: New vaccines could be tested, and if they worked, serve as a firewall in future epidemics. It now appears this chance is slipping away amid public health officials' squabbles over the right way to test vaccines. As a consequence, there... More...>>
04/09/20151:28AMSEEKIs Biogen A Buy? An Analysis Of Its Growth Drivers And Challenges
http://seekingalpha.com/article/3058706-is-biogen-a-buy-an-analysis-of-its-growth-drivers-and-challenges?source=partner_advfn More...>>
04/08/20154:50PMTMFWhy Advaxis Inc. Shares Soared Today
http://www.fool.com/investing/general/2015/04/08/why-advaxis-inc-shares-soared-today.aspx?source=eptadnlnk0000002 More...>>
04/08/201512:38PMSEEKMerck's Buyback Report Card
http://seekingalpha.com/article/3054906-mercks-buyback-report-card?source=partner_advfn More...>>
04/08/20159:57AMDJNMerck Gets Breakthrough Designation for Hepatitis C Drugs -- Update
By Angela Chen Merck & Co. said Wednesday that its hepatitis C drugs have been designated breakthrough therapies by the U.S. Food and Drug Administration. The news comes three months after the agency said it would rescind breakthrough designation due to the introduction of competing treatments for the liver disease... More...>>
04/08/20159:00AMDJNMerck Gets Breakthrough Designation for Hepatitis C Drugs
Merck & Co. said Wednesday that its hepatitis C drugs have been designated breakthrough therapies by the U.S. Food and Drug Administration. The news comes three months after the agency said it would rescind breakthrough designation due to the introduction of competing treatments for the liver disease. The drugs, grazoprevir... More...>>

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nyse mrk150419 06:59